GANYMED increases Series C Financing in Second Closing to Euro 37.2 Million
Hans-Beat Gürtler joins GANYMED Supervisory Board
At the same time, GANYMED announced the election of Hans-Beat Gürtler as a new member of the Supervisory Board. Mr. Gürtler replaces Dr. Harald Poth, who will continue to represent LBBW as observer to the Supervisory Board.
Dr. Rainer Wessel, CEO of GANYMED, commented:
"This additional funding from ATS will allow us to further leverage the development of our cancer antibody projects. And we very much welcome Hans-Beat Gürtler as member of the Supervisory Board. GANYMED will benefit strongly from his extensive experience."
Dr. Thomas M. Rinderknecht, Chairman of the Company's Supervisory Board, added:
"I am delighted to welcome Hans-Beat Gürtler on our board. His outstanding experience will contribute greatly to validate GANYMED as one of the preeminent cancer antibody companies. The additional funding further shows the support and trust of important investors in GANYMED and its outstanding team of scientists."
Mr. Gürtler commented:
"I am delighted to be joining GANYMED's Supervisory Board and hope to contribute to GANYMED's future success in developing truly novel antibody therapeutics against solid cancers with high unmet medical needs."
Hans-Beat Gürtler brings extensive management, marketing and financial experience from more than 30 years with Ciba-Geigy's and Novartis' agricultural and animal health businesses, both in Switzerland and abroad. Until 2002, he was CEO of Novartis' Animal Health business where, under his responsibility, the business quadrupled to a size of more than CHF 1 billion turnover and over 2,200 staff world-wide. Mr. Gürtler also has extensive experience in Mergers and Acquisitions. In late 2002, he joined VARUMA, a private investor. Hans-Beat Gürtler currently serves as a board member and president in several companies.
GANYMED Pharmaceuticals AG
GANYMED is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers. The Company's discovery engine is one of the most powerful integrated solutions to building an antibody cancer pipeline in the industry. This is because GANYMED has brought together arguably the strongest and most dynamic scientific team for systems medicine.
With a world leading expertise in pinpointing highly specific proprietary targets, GANYMED is building a growing sustainable pipeline of antibody therapeutics targeting solid cancers with high medical need and large market potential. The Company's antibody products target the uniquely tumour specific cell surface antigens GC182 and GT468 as therapeutics for the blockbuster markets of gastric, breast, oesophageal, pancreatic and lung cancer. GANYMED is a privately held company located in Mainz, Germany. For further information please visit www.ganymed-pharmaceuticals.com.